#United States #Denver #Rare Diseases #Orphalan #Wilson Disease

Orphalan at The Liver Meeting® 2026

Orphalan Inc., the U.S. branch of a global pharmaceutical company, is set to make a notable impression at The Liver Meeting® 2026, organized by the American Association for the Study of Liver Diseases (AASLD) taking place from November 5 to 9, 2026, in Denver, Colorado. This annual gathering brings together leading medical professionals to discuss the latest advancements in liver disease research.

At this year’s event, Orphalan will present an impressive body of work, including five poster presentations and one oral presentation focusing on Wilson disease—a rare disorder that affects copper metabolism in the body. This deadly condition is due to mutations in the ATP7B gene, leading to the toxic accumulation of copper in organs, particularly in the liver and brain. Left untreated, Wilson disease can result in serious hepatological, neurological, and psychiatric issues, often culminating in fatal outcomes.

Cutting-Edge Research on Wilson Disease

Among the featured research at the meeting is a poster presentation titled "Can a Novel Instant Release Trientine Tetrahydrochloride Formulation Be Effective When Administered Once-Daily? Results of the TRIUMPH-3 Pharmacokinetic Study", which has earned a Poster of Distinction. Dr. Michael Schilsky, a noted figure in liver disease research, will lead the presentation, offering insights into an innovative treatment regimen that could revolutionize patient care.

Another key presentation by Dr. Schilsky will explore "Real-World Evidence of Therapy Impact of Non-Ceruloplasmin Bound Copper by Speciation as a Novel Monitoring Tool in Newly Diagnosed Wilson Disease." This research underscores the importance of monitoring disease progression in newly diagnosed patients, thereby enhancing treatment outcomes through personalized approaches.

Orphalan's scientific contributions extend to educational initiatives as well. A presentation titled "Virtual CME Simulation Improves Multi-Specialty Performance in the Diagnosis and Management of Wilson Disease" will be delivered by Dr. Jovana Lubarda. This study aims to demonstrate how improved training and educational tools can foster better healthcare professional performance in diagnosing and managing Wilson disease.

Furthermore, Dr. Emmanuel Tsochatzis will present findings on patient experiences and treatment adherence based on qualitative interviews and outcomes from ongoing trials. His work titled "Understanding the Drivers of Treatment Experience and Adherence in Wilson Disease" will shed light on patient-centered care strategies essential for enhanced treatment adherence in this rare population.

A Focus on Patient-Centric Approaches

In a compelling discussion regarding decentralized clinical trials, Dr. Tsochatzis will explore how incorporating patient voices can significantly influence tolerability and satisfaction with new treatment modalities. These presentations reflect Orphalan's broader commitment to addressing unmet needs in the Wilson disease community through robust clinical research and patient engagement.

Industry Theater Session

In addition to research presentations, Orphalan will host an industry theater session titled "Peer to Peer Series on Wilson Disease: Unmet Needs, Strategies for Long-Term Management, and the Role of an Approved Treatment Option." Scheduled for November 8, 2026, this session will be led by Dr. Robert G. Gish and is aimed at providing healthcare professionals with strategies for managing Wilson disease effectively while highlighting the role of approved therapies.

Conference attendees are encouraged to stop by Booth #1173 to learn more about Orphalan's ongoing efforts in the realm of Wilson disease, including their commitment to research, education, and providing tailored, patient-focused care.

About Wilson Disease and Orphalan

Wilson disease not only represents a significant medical challenge but also represents a spotlight on the importance of research in rare diseases. Orphalan, with its dedication to developing treatments for conditions like Wilson disease and infantile epileptic spasms syndrome, continues to forge partnerships with healthcare professionals and patient communities. Their model is built on a foundation of medical engagement and a long-term vision for sustainable therapy options, ensuring that patients with complex, rare disorders receive the attention and care they deserve. To learn more, visit Orphalan's website.